Dr Reddys launches Posaconazole delayed release tablets in US

News: Dr Reddy’s has launched Posaconazole delayed release tablets, 100 mg, (generic equivalent to NOXAFIL). The NOXAFIL brand and generic had US sales of ~ US$140.8 million (MAT February 2022, IQVIA)

Views: US launch of Posaconazole delayed release tablets (indicated for use in the prevention of fungal infections), is in a niche space with limited competition (five players). Ramp-up in sales and market share gains in such launches will be a key monitorable. We expect Dr Reddy’s US business to grow at a CAGR of 7.5% over FY21-24E to Rs 8750

Impact: Positive